Capsular Polysaccharide Inactivated Tetanus Toxoid Conjugate Vaccine
Capsular Polysaccharide Inactivated Tetanus Toxoid Conjugate Vaccine Uses, Dosage, Side Effects, Food Interaction and all others data.
Haemophilus influenzae type b strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen is an active immunization as a booster dose given intramuscularly to pediatric patients who have received a primary series with a Haemophilus b Conjugate Vaccine that is licensed for primarly immunization. The vaccine contains Haemophilus b capsular polysaccharide (polyribosyl-ribitol-phosphate [PRP]), which is a high molecular weight polymer prepared from the Haemophilus influenzae type b strain 20,752. These are heat inactivated and purified.
Table Of contents
| Trade Name | Capsular Polysaccharide Inactivated Tetanus Toxoid Conjugate Vaccine |
| Generic | Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen |
| Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen Other Names | Haemophilus influenzae type b strain 20752, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine |
| Type | |
| Groups | Approved, Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Indicated for active immunization in pediatric patients 15 months through 4 years of age as a booster dose for the prevention of invasive disease caused by Haemophilus influenzae type b.
Capsular Polysaccharide Inactivated Tetanus Toxoid Conjugate Vaccine is also used to associated treatment for these conditions: Haemophilus Influenzae Infections, Tetanus
Innovators Monograph
You find simplified version here Capsular Polysaccharide Inactivated Tetanus Toxoid Conjugate Vaccine
